Review: Intravenous immunoglobulin and B cells: When the product regulates the producer

Arthritis and Rheumatology

Volumn 67, Issue 3, 2015, Pages 595-603

  Séïté, Jean François ^a   Hillion, Sophie ^a   Harbonnier, Thomas ^a   Pers, Jacques Olivier ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; FAS ANTIBODY; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BULLOUS PEMPHIGOID; CELL DIFFERENTIATION; CELL MATURATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE PRODUCTION; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SIALYLATION; SUBSTITUTION THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UPREGULATION; VASCULITIS; WISKOTT ALDRICH SYNDROME; AUTOIMMUNE DISEASES; DRUG EFFECTS; IMMUNOLOGY;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 84923624727     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38910     Document Type: Review

References (63)

1. Seite JF, Shoenfeld Y, Youinou P, Hillion S,. What is the contents of the magic draft IVIg? Autoimmun Rev 2008; 7: 435-9.
2. Schwab I, Nimmerjahn F,. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13: 176-89.
3. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
4. Kazatchkine MD, Kaveri SV,. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
5. Ballow M,. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011; 127: 315-23; quiz 24-5.
6. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, et al. F(ab)?2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9: 431-8.
7. Rossi F, Sultan Y, Kazatchkine MD,. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol 1988; 74: 311-6.
8. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14: 1303-11.
9. Le Pottier L, Bendaoud B, Dueymes M, Daridon C, Youinou P, Shoenfeld Y, et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007; 27: 257-65.
10. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161: 3781-90.
11. Von Gunten S, Simon HU,. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 2008; 7: 453-6.
12. Hansen RJ, Balthasar JP,. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100: 2087-93.
13. Masson PL,. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683-9.
14. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115: 3440-50.
15. Crow AR, Suppa SJ, Chen X, Mott PJ, Lazarus AH,. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Blood 2011; 118: 6403-6.
16. Bussel JB,. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000; 37: 261-6.
17. Soubrane C, Tourani JM, Andrieu JM, Visonneau S, Beldjord K, Israel-Biet D, et al. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood 1993; 81: 15-9.
18. Samuelsson A, Towers TL, Ravetch JV,. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-6.
19. Bruhns P, Samuelsson A, Pollard JW, Ravetch JV,. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18: 573-81.
20. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-65.
21. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 3497-502.
22. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111: 715-22.
23. Kessel A, Peri R, Haj T, Snir A, Slobodin G, Sabo E, et al. IVIg attenuates TLR-9 activation in B cells from SLE patients. J Clin Immunol 2011; 31: 30-8.
24. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J,. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011; 127: 823-30.e1-7.
25. Araujo LM, Chauvineau A, Zhu R, Diem S, Bourgeois EA, Levescot A, et al. Cutting edge: intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcγRIIIA-dependent mechanisms. J Immunol 2011; 186: 3289-93.
26. Abe Y, Horiuchi A, Miyake M, Kimura S,. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139: 5-19.
27. Lustrek M, Lorenz P, Kreutzer M, Qian Z, Steinbeck F, Wu D, et al. Epitope predictions indicate the presence of two distinct types of epitope-antibody-reactivities determined by epitope profiling of intravenous immunoglobulins. PLoS One 2013; 8: e78605.
28. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-9.
29. Altznauer F, von Gunten S, Spath P, Simon HU,. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003; 112: 1185-90.
30. Reipert BM, Stellamor MT, Poell M, Ilas J, Sasgary M, Reipert S, et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008; 94: 334-41.
31. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S,. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 2010; 116: 1698-704.
32. Toyoda M, Zhang XM, Petrosian A, Wachs K, Moudgil A, Jordan SC,. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human γ-globulin. Transpl Immunol 1994; 2: 337-41.
33. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011; 36: 9-15.
34. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11: 152-8.
35. Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945-9.
36. Mazer BD, Gelfand EW,. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991; 87: 976-83.
37. Sigman K, Ghibu F, Sommerville W, Toledano BJ, Bastein Y, Cameron L, et al. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. J Allergy Clin Immunol 1998; 102: 421-7.
38. Zhuang Q, Mazer B,. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin. J Allergy Clin Immunol 2001; 108: 229-34.
39. Zhuang Q, Bisotto S, Fixman ED, Mazer B,. Suppression of IL-4-and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcγRIIb. J Allergy Clin Immunol 2002; 110: 480-3.
40. Horejs-Hoeck J, Hren A, Mudde GC, Woisetschlager M,. Inhibition of immunoglobulin E synthesis through Fc γRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking. Immunology 2005; 115: 407-15.
41. De Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S,. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003; 101: 3065-73.
42. Neron S, Boire G, Dussault N, Racine C, de Brum-Fernandes AJ, Cote S, et al. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro. Arch Immunol Ther Exp (Warsz) 2009; 57: 447-58.
43. Othy S, Bruneval P, Topcu S, Dugail I, Delers F, Lacroix-Desmazes S, et al. Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation. J Autoimmun 2012; 39: 168-72.
44. Aubin E, Lemieux R, Bazin R,. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010; 115: 1727-34.
45. Paquin Proulx D, Aubin E, Lemieux R, Bazin R,. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol 2010; 135: 422-9.
46. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A,. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-7.
47. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A,. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19: 837-47.
48. Seite JF, Guerrier T, Cornec D, Jamin C, Youinou P, Hillion S,. TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J Autoimmun 2011; 37: 190-7.
49. Dussault N, Ducas E, Racine C, Jacques A, Pare I, Cote S, et al. Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2. Int Immunol 2008; 20: 1369-79.
50. Seite JF, Goutsmedt C, Youinou P, Pers JO, Hillion S,. Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allergy Clin Immunol 2014; 133: 181-8.e1-9.
51. Jefferis R,. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30: 356-62.
52. Kaneko Y, Nimmerjahn F, Ravetch JV,. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-3.
53. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV,. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105: 19571-8.
54. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV,. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373-6.
55. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV,. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475: 110-3.
56. Bayry J, Bansal K, Kazatchkine MD, Kaveri SV,. DC-SIGN and α2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells [letter]. Proc Natl Acad Sci U S A 2009; 106: E24.
57. Ravetch J, Anthony R, Wermeling F, Karlssonb M,. Reply to Bayry, et al. the anti-inflammatory activity of sialylated IgG Fcs. Proc Natl Acad Sci U S A 2009; 106: E25.
58. Leontyev D, Katsman Y, Ma XZ, Miescher S, Kasermann F, Branch DR,. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52: 1799-805.
59. Leontyev D, Katsman Y, Branch DR,. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP. Blood 2012; 119: 5261-4.
60. Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F,. Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol 2014; 44: 1444-53.
61. Poe JC, Tedder TF,. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol 2012; 33: 413-20.
62. Massoud AH, Guay J, Shalaby KH, Bjur E, Ablona A, Chan D, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol 2012; 129: 1656-65.e3.
63. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179: 5571-5.